MannKind Q4 revenue rises 46% as Furoscix sales surge

MannKind

26/02/2026 13:07

Overview

Biopharmaceutical firm's Q4 revenue grew 46% yr/yr

Company completed acquisition of scPharmaceuticals, boosting cardiometabolic franchise

Net loss reported for Q4 despite strong revenue growth

Outlook

MannKind anticipates FDA decisions on Afrezza and Furoscix in 2026

Company expects Nintedanib DPI Phase 1b data in 2H 2026

MannKind sees ADA recommendations boosting Afrezza adoption

Result Drivers

FUROSCIX SALES - Furoscix sales surged 91% in Q4 2025 following the acquisition of scPharmaceuticals, contributing significantly to revenue growth

AFREZZA SALES - Afrezza sales increased 25% in Q4 2025, aided by its inclusion in ADA's 2026 Standards of Care, promoting broader adoption

SC PHARMA ACQUISITION - Acquisition of scPharmaceuticals enhanced MannKind's cardiometabolic franchise, boosting overall revenue

Company press release: ID:nGNX1qDCYh

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$15.95 mln
Q4 Basic EPS
-$0.05
Q4 Operating Income
-$7.69 mln
Q4 Pretax Profit
-$20.93 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for MannKind Corp is $10.00, about 185.7% above its February 25 closing price of $3.50

The stock recently traded at 41 times the next 12-month earnings vs. a P/E of 63 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)